Publisher
Springer Berlin Heidelberg
Reference10 articles.
1. Chey WY, Hussain A, Ryan C, Potter GD, Shah A (2001) Infliximab for refractory ulcerative colitis. Am J Gastroenterol 96(8): 2373–2381
2. Gershon K (2002) Comment. N Engl J Med 346:623
3. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15): 1098–1104
4. Lochs H, Adler G, Beglinger C, Duchmann R, Emmrich J, Ewe K et al. (1999) Anti-TNF antibody in Crohn’s disease — status of information, comments and recommendations of an international working group. Z Gastroenterol 37(6): 509–512
5. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121(5): 1145–1157.